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We performed comparative genomic hybridization (CGH)
and high-resolution deletion mapping of the long arm of
chromosome 2 (2q) in invasive cervical carcinoma (CC).
The CGH analyses on 52 CCs identified genetic losses at
2q33–q36, gain of 3q26–q29, and frequent chromosomal
amplifications. Characterization of 2q deletions by loss of
heterozygosity (LOH) in 60 primary tumors identified two
sites of minimal deleted regions at 2q35–q36.1 and
2q36.3–q37.1. To delineate the stage at which these
genetic alterations occur in CC progression, we analysed
33 cervical intraepithelial neoplasia (CIN) for LOH. We
found that 89% of high-grade (CINII and CINIII) and
40% of low-grade (CINI) CINs exhibited LOH at 2q. To
identify the target tumor suppressor gene (TSG), we
performed an extensive genetic and epigenetic analyses of
a number of candidate genes mapped to the deleted
regions. We did not find inactivating mutations in
CASP10, BARD1, XRCC5, or PPP1R7 genes mapped
to the deleted regions. However, we did find evidence of
downregulated gene expression in CFLAR, CASP10 and
PPP1R7 in CC cell lines. We also found reactivated gene
expression in CC cell lines in vitro after exposure to
demethylating and histone deacetylase (HDAC) inhibiting
agents. Thus, these data identify frequent chromosomal
amplifications in CC, and sites of TSGs at 2q35–q36.1
and 2q36.3–q37.1 that are critical in CC development.
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Introduction
Cervical carcinoma (CC) is the second most common
malignancy among women in both incidence and
mortality (NIH Consensus Statement, 1996). Although
much is known about the etiology and treatment of CC,
the role of genetic alterations in the multistep pathway
of cervical tumorigenesis is largely unknown. Conver-
ging points of evidence implicate infection by high-risk
human papilloma virus (HPV) types as a critical
etiologic factor (Kubbutat and Vousden, 1996). Epide-
miological and experimental data, however, show that
only a small fraction of HPV-infected cervical intrae-
pithelial neoplastic (CIN) lesions progress to invasive
CC (Murthy et al., 1990; Ostor, 1993; zur Hausen and
Rosl, 1994). These findings, therefore, suggest that other
somatic genetic mutations play a major role in the
initiation and progression of CC. Delineation of these
genetic changes is critical in understanding the mole-
cular basis of CC.
The development of CC is preceded by distinct
morphological changes from normal epithelium to
carcinoma through low-grade and high-grade squamous
intraepithelial lesions (SILs), which represent mild to
severe dysplasias. The genetic basis of this progression is
poorly understood. Molecular studies on early and
invasive CC has identified several structural and
functional alterations in oncogenes and candidate tumor
suppressor gene (TSG) sites (Lazo, 1999). Despite this
molecular characterization of cervical precancerous and
cancerous lesions, no critical genes or chromosomal
regions that play role in the development of CC have
been identified so far. Studies on comparative genomic
hybridization (CGH) have identified chromosomal
changes involving loss of 2q, 3p, 4p, 4q, 5q, 6q, 11q,
13q, and 18q regions and gain of 1q, 3q, 5p, and 8q
regions at various stages of CC (Heselmeyer et al., 1996,
1997; Dellas et al., 1999; Kirchhoff et al., 1999; Hidalgo
et al., 2000; Umayahara et al., 2002). Although a limited
number of CGH studies (Heselmeyer et al., 1997;
Hidalgo et al., 2000) and low-resolution loss of
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heterozygosity (LOH) mapping (Rader et al., 1998;
Kersemaekers et al., 1999) have provided evidence of
recurrent deletions on the 2q in invasive CC. The precise
site of deletions that harbor putative TSG is unknown
because of the lack of systematic and detailed deletion
mapping studies.
In our attempts to discover critical genetic changes in
CC progression, in the present study we first identified
2q33–q36 deletions, 3q gains, and chromosomal ampli-
fications as the characteristic genetic changes by CGH.
Followed by this, we identified two common minimal
deleted regions of allelic loss at 2q35–q36.1 and 2q36.3–
q37.1 by high-resolution LOH mapping. The 2q genetic
alterations have also been found at early stages of
progression in high- and low-grade CINs, suggesting
that these changes affect genes critical in tumor
progression. Furthermore, we have excluded several
known candidate genes mapped to these regions as
targets of mutational inactivation suggesting either the
presence of so far unidentified gene(s) or alternative
mechanisms of loss of tumor suppression resulting from
2q genetic loss. Gene expression analysis identified lack
of or downregulated expression of a number of genes
mapped in the proximity of the common regions of
LOH. We have also observed reactivation of gene
expression upon exposure of cells to demethylating and
histone deacetylase (HDAC) inhibiting agents without
evidence for hypermethylation of promoter sequences.
These results, therefore, imply that the 2q genetic loss
occurs very early in progression and the gene(s) affected
may play an important role in cervical tumorigenesis.
Results
CGH identified a common site of deletion at 2q33–q36,
gain of 3q26–q29, and frequent chromosomal
amplifications in invasive CC
We have performed CGH analysis of 52 DNAs from
invasive CCs (44 primary tumors and eight cell lines),
and the results are summarized in Figure 1. Under-
representation of DNA copy number in X25% tumors
was noted at chromosomal regions 2q (65%), 13q
(36.5%), 4p (34.6%), 17p (32.7%), 11q (32.7%), 4q
(30.8%), and 18q (25%). Chromosomal gains in >15%
of tumors were identified at 3q (52%), 5p (32.7%), 8q
(26.9%), 20q (25%), 9q (23.0%), 14q (15.4%), and 1p
(15.4%). Although the pattern of chromosomal changes
observed in both primary tumors and cell lines was
similar, the DNA copy number losses predominated in
primary tumors (65% losses versus 35% gains). How-
ever, the cell lines exhibited almost identical frequencies
of DNA losses and gains (47 and 53%).
The most striking observation of the CGH analysis
was the identification of loss of chromosome 2 regions in
34 (65%) tumors. All eight cell lines studied exhibited 2q
losses, while 26 (59%) of the primary tumors had losses.
Mapping CGH losses identified an overlapping region
between 2q33 and q36 in all tumors that showed
deletions on 2q (Figure 1). Thus, the chromosome
2q33–q36 region was identified as a common site of
deletion in a high proportion of CCs. These data,
therefore, suggest that the 2q33–q36 region contain one
or more genes that are critical for CC tumorigenesis.
Of the DNA copy number gains seen in CC, the 3q
was most frequently affected. We found 3q copy number
gains in 24 (54.5%) of the primary tumors and in three
(37.5%) of the cell lines studied. The common region of
gain identified in the present study was 3q26–q29.
We identified 20 high-level chromosomal amplifica-
tions at 15 different chromosomal sites in 15 of 52
(28.8%) tumors studied. The amplifications were noted
at 1p31, 2q32, 3q21, 7p11.2–p12, 7q22–q31, 8q23–q24,
9p22, 10q21, 10q24, 11q13, 11q21, 12q15, 16q23–q24,
20q11.2, and 20q13.1 (Figure 1). Recurrent sites of
amplification were noted in four chromosomal sites:
7p11 (Ca Ski and MS751), 8q23–q24 (CC102 and Ca
Ski), 11q13 (CC52, MS751, and HT-3) and 11q21 (CC98
and CC116). Nonrecurring amplifications were found at
1p31 (CC24), 2q32 (CC968), 3q21 (SiHa), 7q22–q31
(CC892), 9p22 (CC86), 10q21 (ME-180), 10q24
(CC968), 12q15 (CC52), 16q23–q24 (SiHa), 20q11.2
(SW756), and 20q13.1 (C-33A). These data, therefore,
suggest that gene amplification is a common genetic
alteration in this tumor type. Our results suggest that the
2q33–q36 losses, the 3q26–q29 gains, and chromosomal
Figure 1 Ideogram showing DNA copy-number changes identi-
fied by CGH in 44 primary tumors and eight cell lines derived from
CC. Thin vertical lines on either side of the ideogram indicate losses
(left) and gains (right) of chromosomal region. The chromosomal
regions of the high-level amplification were shown in thick lines
(right)
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amplifications are characteristic genetic changes in
invasive CC.
High-resolution deletion mapping in invasive CC identifies
two minimal deleted regions of LOH at 2q35–q36.1 and
2q36.3–q37.1
To further characterize the 2q losses identified by CGH
analysis, we evaluated LOH in 60 primary CCs, using 31
STRP markers mapped to this chromosomal arm
(Figure 2). A total of 41 of these tumors were also
studied by CGH. We found LOH of at least one marker
in 37 (61.7%) of the tumors. Two of these tumors
showed LOH at all the informative markers, while the
remaining 35 tumors exhibited partial deletions on 2q.
The patterns of LOH from the 33 tumors with partial
losses identified two common sites of minimal deletions
at the 2q36.3–q37.1 and 2q35–q36.1 regions (Figure 2).
The 2q36.3–q37.1 minimal deletion derived from 32
tumors span six markers (D2S1392, D2S427, D2S2176,
D2S206, D2S331, and D2S2348). The deletion bound-
aries were identified based on the patterns of LOH in at
least five tumors (T-29, T-869, T-939, T-968, and T-
1068) (Figure 2). The 2q35–q36.1minimal deletion
spans five STRP loci (D2S163, D2S120, D2S377,
D2S339, and D2S126) and was identified based on the
patterns of LOH in 26 tumors. The 2q35–q36.1 deletion
boundaries were identified from the pattern of LOH in
at least six tumors (T-93, T-63, T-98, T-58, T-70, T-28,
and T-21) (Figure 2). A total of 21 tumors commonly
exhibited LOH at both sites of minimal deletions,
whereas nine tumors had deletions only at 2q36.3–
q37.1 and three had deletions only at the 2q35–q36.1
region (Figure 2). The 2q36.3–q37.1 deletion spans a
10.6-cM distance between 242.4 and 253 cM on the
genetic map, and the 2q35–q36.1minimal deletion maps
to a 6.8-cM distance between 223.2 to 230 cM on the
genetic map. Thus, our deletion analysis identified two
distinct but closely mapped sites of common regions of
deletions on 2q in CC.
2q deletions occur in cervical precancerous lesions
To evaluate whether the 2q genetic losses occur early in
the progression of CC, we studied LOH in 33 cervical
intraepithelial neoplasia (CIN) specimens (28 high-grade
and five low-grade lesions) using six STRP markers
mapped to 2q23–2q37.2 regions. In total, 25 of 28
(89.3%) high-grade CINs exhibited LOH in at least one
informative locus. Of the five low-grade CINs, two
(40%) had LOH (Figure 3). Consistent with the
localization of common deleted regions to the distal 2q
in invasive CC, the CINs also had a higher incidence of
LOH with the markers D2S1392, D2S2176, and
D2S2348 mapped to 2q36.3–q37.1 regions compared
to the proximal marker D2S321, which maps to the 2q23
region and the distal marker D2S338 that maps to
2q37.2 (Figure 3). The finding of 2q deletions in both
low-grade and high-grade CINs suggests that these
genetic alterations occur at very early stages in the
development of CC.
Analysis of candidate genes at the 2q deleted regions
Lack of inactivating mutations in PPP1R7, BARD1,
XRCC5, and CASP10 genes Despite the well-defined
morphologic changes at various stages in the develop-
ment, the genetic alterations associated with the initia-
tion and progression of CC are unclear. To find
inactivated genes at the 2q36.3–q37.1 and 2q35–q36.1
minimal deleted regions, we identified genes with
potential tumor suppressor function mapped to these
regions by searching the human genome resources at the
NCBI web site (http://www.ncbi.nlm.nih.gov/genome/
guide/human/). We identified three candidate genes for
tumor suppressor function, NCL, NEDD5 and
PPP1R7, in the vicinity of the 2q36.3–q37.1 deletion.
The PPP1R7 gene encodes a protein phosphatase 1,
regulatory subunit 7 that is required for the completion
of mitosis in Saccharomyces pombe (Renouf et al., 1995).
The NEDD5 gene plays an essential role in cytokinesis
(Kinoshita et al., 1997). The NCL, nucleolin, gene is a
major nucleolar protein in growing eucaryotic cells; it
induces chromatin decondensation by binding to histone
H1. Although NCL is upregulated in proliferating cells,
its multiple roles in the cell cycle implicate this gene in
the regulation of cell growth (Srivastava and Pollard,
1999). We analysed the PPP1R7 gene for mutations in
30 primary tumors with a 2q36–q37 region of LOH and
did not find any inactivating genetic alterations.
The vicinity of 2q35–q36.1 deleted region contains
five potential TSGs. These are BARD1, XRCC5,
CFLAR, CASP10, and CASP8. The BARD1 gene,
which encodes brca1-associated ring domain protein, is
implicated in brca1-mediated tumor suppression, cell
growth regulation, and the cellular response to DNA
damage in vitro (Wu et al., 1996). The BARD1 gene has
earlier been shown to exhibit infrequent mutations in
sporadic and hereditary breast, ovarian, and endome-
terial tumors (Thai et al., 1998). In view of the high
frequency of 2q35–q36.1 deletions in cervical precancer-
ous and cancerous lesions, and the chromosomal
localization of the BARD1 gene at this region, we
analysed 73 DNA samples from invasive CC for
mutations. We found a very high frequency of
conformational variations in CC. Follow-up studies on
DNA from the corresponding blood specimens, together
with sequencing analysis confirmed these changes as
polymorphic variants (Table 1). We found 12 different
single-nucleotide alterations in the BARD1 gene. All of
these were within the coding region except two that were
in the 50 noncoding sequence (Table 1). One of these two
was a splice donor variant of exon 3. In addition, we
found a two base pair AT deletion in intron 2. Both
these changes were also found in the corresponding
normal DNA. Thus, our extensive mutation analysis
excluded BARD1 as the target of mutational inactiva-
tion at 2q35–q36.1 deletions in CC.
The XRCC5 gene mapped to 2q35 encodes the 80-
kDa subunit of the Ku autoantigen. The Ku80 is
essential for maintaining genomic integrity through its
ability to bind DNA double-strand breaks and to
facilitate repair by the nonhomologous end-joining
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Figure 2 Identification of minimal regions of deletions by high-resolution LOH mapping on 2q in invasive CC. Patterns of LOH. A total of 33 tumors with partial deletions are represented. A G-
banded ideogram of chromosome 2 is shown on top. Thick horizontal lines shown below the 2q ideogram represents the corresponding chromosomal regions. Small vertical lines show STRP markers
on the thick horizontal lines and their corresponding genetic map distances. The percentage of LOH is shown in horizontal box below each STRP marker. The patterns of LOH are shown below. For
the clarity of presentation, derivation of two minimal deleted region at 2q35–q36.1 (left panel) and 2q36.3–q37.1 (right panel) are separated. A horizontal line represents each tumor; marker region
with LOH is shown by light shaded lines, and dark shaded lines show the retention of heterozygosity. Tumor numbers are shown on the right or the left of horizontal lines. Shaded tumor numbers




























pathway in mammalian cells (Taccioli et al., 1994).
XRCC5 functions as a caretaker gene, acting synergis-
tically with the loss of p53 in mice. XRCC5//p53/
mice exhibit hypersensitivity to gamma radiation and
develop a spectrum of cancers, including pro B-cell
lymphomas with specific chromosome translocations
and gene amplifications (Difilippantonio et al., 2000;
Lim et al., 2000). As expression of the high-risk HPV E6
gene results in functional inactivation of p53 through
binding and degradation (Munger et al., 1992), the
XRCC5 could be a strong candidate TSG at the 2q35–
36.1 deletion. However, our mutation analysis of this
gene in 30 cases of CC provided no evidence of the
presence of inactivating mutations (Table 1).
The CFLAR, CASP10, and CASP8 genes, which
encode functionally related cysteine proteases and play a
central role in apoptosis, have been mapped within a
150-kb genomic region proximal to the BARD1 gene at
the 2q35–q36.1 minimal deletion (Fernandes-Alnemri
et al., 1996; Shu et al., 1997). These caspases have been
implicated in various diseases, including cancer. For
example, germline mutations in the CASP10 gene result
in autoimmune lymphoproliferative syndrome, type II;
ALPS2 (Wang et al., 1999). Caspase 8 has been shown
to function as a tumor suppressor resulting from 2q
deletions in neuroblastoma (Teitz et al., 2000, 2001;
Takita et al., 2001). To assess the role of the CASP10
gene in cervical tumorigenesis, we performed mutation
analysis in 22 primary tumors and eight cell lines. We
found no pathogenic mutations in the CASP10 gene,
except two single-nucleotide changes that were present
in both the tumors and the corresponding normal
DNAs (Table 1). Thus, we conclude that the four
candidate genes we tested so far are not targets of
mutational inactivation of 2q deletions in CC.
Gene expression and methylation analysis in CC cell
lines In a further effort to identify the mechanisms of
gene inactivation involved in the recurrent 2q deletions
in CC, we performed a semiquantitative RT–PCR
analysis on eight genes (CFLAR, CASP8, CASP10,
BARD1, XRCC5, NCL, NEDD5, and PPP1R7) in eight
CC cell lines (Figure 4a). Five of these genes (CASP8,
BARD1, XRCC5, NCL, and NEDD5) showed no
evidence of downregulated expression relative to their
Figure 3 Identification of 2q LOH in high-grade and low-grade CINs. (a) Pattern and frequency of LOH in CINs. In total, 14 high-
grade and five low-grade CINs studied are shown on top. The STRP markers studied and their patterns of LOH are shown below.
Filled square, LOH; hatched square, retention of heterozygosity; empty square, homozygous and uninformative; ND, not done.
Percentage of LOH of each marker is shown on right in the box. (b) Illustration of LOH in CINs. C-16 is a low-grade CIN and C-6
represents a high-grade CIN. The STRP markers and the CIN numbers are shown above each panel. N, normal; C, CIN; Asterisks
indicate LOH
Table 1 Nucleotide variations in genes mapped to the common







BARD1 A26G Noncoding region 7
C44G Noncoding region 7
C143T Pro24Ser 12












XRCC5 T1218C Tyr395Tyr 1
A58416G (intron 12)b — 2
C1590T Pro519Leu 1
G2361C Noncoding region 5
T2263A Noncoding region 1
CASP10 C402G Leu70Val 1
C1293T Val367Ile 2
aThe frequency is based on combined SSCP and sequencing data. bThe
nucleotide number is based on the clone AC009521
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levels in the normal cervix. The remaining three genes
(CFLAR, CASP10, and PPP1R7) exhibited relative
decrease in expression in some cell lines. The most
striking observation of this analysis was the complete
lack of expression, using two different sets of RT–PCR
primers, of CASP10 in the C-33A cell line (Figure 4a).
In addition, expression of the CASP10 gene was also
reduced in one other cell line (Ca Ski). Thus, two (25%)
of the CC cell lines studied showed evidence of
downregulated gene expression. Expression of CFLAR,
another caspase gene in this cluster, was also showed
decreased expression in the same two cell lines (Ca Ski
and C-33A). Expression of the PPP1R7 gene was
downregulated in three (37.5%) of the cell lines (C-
33A, SiHa, and MS751) (Figure 4a). These results,
therefore, suggest that several genes mapped to the 2q
deletions have downregulated steady-state levels of gene
expression in CC cell lines. Since we found no
pathogenic mutations in CC cell lines and primary
tumors in CASP10 and PPP1R7 genes, these results also
suggest that another genetic or epigenetic gene inactiva-
tion mechanism may be involved.
To identify the possible epigenetic mechanism, we
treated CC cell lines with a demethylating drug 5-Aza-20
deoxycytidine, and an inhibitor of HDAC, n-butyrate.
Demethylation of promoter regions and inhibition of
histone deacetylation has been shown to reactivate gene
expression by 5-Aza-20 deoxycytidine and n-butyrate,
respectively (Tycko, 2000). Some of the cell lines treated
with these drugs either separately or in combination
have shown reactivation of gene expression as compared
to untreated cells (Figure 4b). However, one of the
caspase genes, CASP10, did not show any evidence of
reactivation of mRNA after treatment including the C-
33A cell line that showed the complete lack of
expression (Figure 4b). The CFLAR gene was reacti-
vated either after the treatment to 5-Aza-20 deoxycyti-
dine or combined with n-butyrate in two cell lines
(CaSki and C-33A) that showed downregulated expres-
sion. In addition, another cell line (SW756) that showed
no relative decrease in expression in untreated cells also
showed reactivation to these drugs (Figure 4b). The
CASP8 gene that did not show evidence of down-
regulated expression showed reactivation in all eight cell
lines studied. Similarly, the BARD1 that did not show
downregulated expression showed reactivation in three
of eight cell lines (Figure 4b). The PPP1R7 gene was
reactivated in two of three cell lines that showed
downregulated expression and another cell line (CaSki)
that did not show reduced expression also showed
reactivation (Figure 4). Thus, these data suggest that
both the demethylating agent and the deacetylase
inhibitor have the potential ability to reactivate gene
expression over the basal levels.
We then tested to see if this gene reactivation was
because of promoter hypermethylation. We searched the
50 end of genomic sequences of the genes included in this
study for CpG islands using Grail Experimental Gene
Discovery software (http://grail.lsd.ornl.gov/grailexp/).
This analysis has identified that the BARD1 and
PPP1R7 genes each contain an approximately 2 kb
CpG island spanning exon 1 and intron 1 at the 50 end of
the gene. We also found two CpG islands spanning 600
and 360 bp of DNA located, respectively, 14 and 15 kb
upstream of CFLAR, in the caspase gene cluster.
Methylation-specific PCR of the CpG islands followed
by sequencing of at least 200 bp of each CpG yielded no
evidence of CpG hypermethylation in these genes (data
not shown). Thus, our data suggest that extensive
hypermethylation does not occur in these genes in CC,
but that the reactivation of gene expression occurs in
response to demethylating or HDAC-inhibiting agents.
Discussion
Our CGH analysis identified a consensus region of
deletion at 2q33–q36 regions in all 34 cervical tumors
that showed 2q losses. Previous CGH studies have
shown a low frequency of genetic losses at 2q in
precancerous lesions, CIS, and invasive CC (Heselmeyer
et al., 1996; Dellas et al., 1999). Thus, the identification
of a high incidence of 2q33–q36 losses in CC strongly
Figure 4 Analysis of gene expression in CC cell lines. (a)
Semiquantitative multiplex RT–PCR analysis of 2q candidate
genes. The C-33A cell line showed complete lack of expression in
CASP10 gene. Reduced expression was found in CFLAR (Ca Ski
and C-33A), CASP10 (Ca Ski), and PPP1R7 (C-33A, SiHa and
MS751). (b) Effect of demethylation and acetylation on gene
expression. Note the lack of reactivation of gene expression in C-
33A in CASP10. Lane 1, untreated; lane 2, butyrate-treated; lane 3,
5-Aza-20 deoxycytidine+butyrate treated, and lane 4, 5-Aza-20
deoxycytidine-treated. Genes are shown on left; cell lines are
indicated on top (panel ‘‘a’’) or bottom (panel ‘‘b’’); arrowhead
indicates the PCR product of actin gene used as control and arrow
represents the indicated gene
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suggests that this region harbor one or more tumor
suppressor genes. Of the DNA copy-number gains seen
in CC, the 3q was most frequently affected. The
common region of gain identified in the present study
was 3q26–q29, which is identical to that in most
previously reported studies (Heselmeyer et al., 1996,
1997). The gain of 3q genetic material has been shown in
a diverse types of tumors, with highest prevalence of
gain occurring in carcinomas of mucosal origin, includ-
ing those arising from the head and neck, cervix, lung,
and esophagus (http://www.nhgri.nih.gov/DIR/LCG/
CGH/index.html). In CC, it has been demonstrated
that copy-number gains in the 3q region are associated
with progression from high-grade cervical intraepithelial
neoplasia to invasive cancer (Heselmeyer et al., 1996). A
number of candidate genes have been identified on
3q26–q27 regions implicated as candidate oncogenes in
carcinomas of the cervix, ovary, and head and neck
(Shayesteh et al., 1999; Ma et al., 2000; Singh et al.,
2001).
Increase in gene dosage by DNA amplification is a
common mechanism to achieve overexpression of genes
in tumors. It has been shown that gene amplification
commonly is associated with tumor progression, resis-
tance to chemotherapy, and poor clinical outcome in a
variety of tumor types (Schwab, 1999). However, the
scope of gene and chromosomal amplifications has been
limited in CC (Mitra et al., 1994). In the present study,
we identified a high frequency of amplified chromoso-
mal sites in CC. These data, therefore, comprise the first
distinct evidence of chromosomal amplification in CC.
Several of the amplified sites in the present study are of
particular interest, such as 8q24 region, which harbors
the MYC gene. A recently identified protein tyrosine
phosphatase (PRL3) gene, which also maps to 8q24, is
expressed at high levels in metastatic colon cancer (Saha
et al., 2001). It has been shown that the amplified
CCND1/PRAD1 gene on 11q13 is overexpressed in CC
cell lines (Kurzrock et al., 1995). A newly identified
A1B1 gene on 20q12 is frequently amplified and
overexpressed in breast tumors, although its exact role
is not yet known (Anzick et al., 1997). Thus, the
identification of many chromosomal regions of ampli-
fication in the present study suggests that gene
amplification is a common genetic alteration in invasive
CC. Further molecular characterization of the amplified
regions should facilitate identification of the target
amplified genes in CC. Thus, in the present study, we
identified a novel site of deletion at the 2q33–q36,
confirmed the previously reported gains in the 3q26–q29
region and identified frequent occurrence of gene
amplifications. Our results, therefore, suggest that these
are the characteristic genetic changes in invasive CC.
To identify the critical regions of deletion on 2q, we
performed high-density LOH mapping and identified
two common regions of deletions at cytogenetic bands
2q36.3–q37.1 and 2q35–q36.1. The major site of deletion
at 2q36.3–q37.1 spans a 4.7-Mb physical distance
exhibiting LOH in 32 of 37 (86.5%) tumors that showed
2q losses. Consistently, the marker D2S427 mapped to
this region exhibited the highest frequency (65.9%) of
LOH (Figure 2). The second region at 2q35–q36.1,
spanning a 4.8-Mb physical distance, exhibited deletion
in 26 of 37 (70%) tumors that showed 2q LOH. Among
the 41 primary invasive CCs that we studied for both
CGH and LOH, the results were compatible in 35
tumors by both methods. In the other six tumors, which
showed copy-number losses by CGH, did not exhibit
LOH. It is likely that the LOH analysis was not sensitive
enough to detect losses in specimens containing less than
50% tumor cells, while the CGH might be more
sensitive in detecting these changes. However, our
extensive deletion mapping allowed us to identify two
distinct sites of minimal deletions, providing evidence of
the existence of critical TSGs at these regions.
The 2q33–37 region has been shown to affect a
number of other tumor types, including neuroblastoma
(Takita et al., 2001), as well as carcinomas of lung
(Otsuka et al., 1996), head and neck (Ransom et al.,
1998), esophagus (Hu et al., 2000), and follicular thyroid
(Tung et al., 1997). It has also been shown that the 2q
LOH has associated with advanced stage cancer and
predicts a poor prognosis for patients with head and
neck cancer and follicular thyroid carcinoma (Tung
et al., 1997; Ransom et al., 1998). 2q37 microcell hybrids
effectively restore cellular senescence in the CC cell line
SiHa, identifying a putative senescence gene to this
region (Uejima et al., 1998). Thus, one or more genes
that control cell growth and senescence are likely to be
located on 2q35–37 and may play a common role in
different tumor types.
To identify target genes at these deletions, we
performed semiquantitative gene expression in CC cell
lines. This analysis identified CFLAR and CASP10
(mapped to 2q34–q35), and PPP1R7 (mapped to
2q36.3–37.1) genes as having downregulated steady-
state levels of gene expression in a number of cell lines.
As downregulated gene expression is not a sole criterion
for identifying TSGs, we then performed mutation
analysis of the entire coding regions of the CASP10,
BARD1, XRCC5, and PPP1R7 genes in primary tumors
that showed LOH on 2q and in cell lines. Direct
sequencing of all SSCP variants suggested that none of
these genes exhibit inactivating mutations in CC.
Surprisingly, the BARD1 genomic region is highly
polymorphic showing at least 87 variants in the 73
tumor DNAs studied (Table 1). The majority of the
variants that we found have also been reported in the
single-nucleotide polymorphism (SNP) database (http://
www.ncbi.nlm.nih.gov/SNP/) and by a previous study
(Thai et al., 1998). In addition, we found several variants
that have not been reported earlier, including a splice
donor variant in exon 3. We found five changes in
XRCC5 gene, two in the coding region and three in
either the noncoding region or in intronic sequence
(Table 1). All changes except Pro519Leu were confirmed
as polymorphisms by their presence in the correspond-
ing constitutional DNA. We have also found two SNPs
in the coding region of the CASP10 gene that are not in
the SNP database (Table 1). Germline mutations in the
CASP10 gene have been shown to cause defective
lymphocyte and dendritic cell apoptosis in ALPS type II
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(Wang et al., 1999). The V367I polymorphism that we
found in two tumors has previously been reported in
ALPS patients as an inherited mutation that causes
decreased apoptotic activity. Whether or not these
polymorphisms have any effect on the efficiency of
apoptotic mechanisms in tumors remains to be investi-
gated.
Since we obtained evidence of downregulated expres-
sion of several genes in the absence of inactivating
mutations, we tested to see if this downregulation was a
consequence of epigenetic mechanisms. We found
detectable upregulation in expression of four of the five
genes tested upon exposure to 5-Aza-20 deoxycytidine, n-
butyrate, or combination of the two. To determine
whether or not promoter hypermethylation plays a role
in reactivation, we performed methylation-specific PCR,
and then sequenced a part of the CpG islands of BARD1
and PPP1R7. We also tested two CpG islands upstream
of the caspase gene cluster. We did not find any evidence
of methylation. Thus, we ruled out extensive promoter
hypermethylation as the mechanism of inactivation of
these genes. The absence of CpG islands in the proximal
promoter regions of caspase genes and their reactivation
by methylation and HDAC inhibitors suggests an
indirect mechanism of epigenetic gene downregulation
affecting the transactivating regulators or transcription
factors by methylation (Soengas et al., 2001; Zhu et al.,
2001). However, the cell line C-33A, which showed com-
plete lack of expression of CASP10, did not reactivate in
response to 5-Aza-20 deoxycytidine or n-butyrate
(Figure 4b). Complete absence of the expression may
also result from lack of primer binding because of
polymorphism. However, this possibility was ruled out
since we have tested two different sets of primers to
amplify the CASP10 gene. The fact that SSCP analysis
of the C-33A cell line did not show mutations in the
coding region of CASP10 excludes homozygous deletion
as a mechanism for the loss of gene expression. Thus,
gene inactivation in this cell line may be the result of
other mechanisms such as a promoter mutation.
The high frequency of 2q loss of genetic material and
the identification of regions of critical deletions strongly
indicate that these regions harbor TSGs. Thus, it is
possible that there may be other genes that are targets of
mutational inactivation at 2q35–q36.1 and 2q36.3–q37.1
in CC. The partial downregulation of expression and the
reactivation of genes mapped to the minimal deletions
is, however, intriguing. It is possible that several genes
are influenced by genetic alterations of the region and
that their downregulation below physiologic levels is
associated with disease progression. Our data on
restoration of expression to physiologic levels following
exposure to demethylating agents, in the absence of
demonstrable promoter hypermethylation, suggest that
the downregulated gene expression may be because of
defects in transcription factors that normally activate
promoters or partial methylation. Such defects may
involve methylation and deacetylation of those tran-
scription factors.
In summary, we have identified two sites of common
regions of frequent deletions at 2q35–q36.1 and
2q36.3–q37.1 in CC that harbor critical TSGs. We
have excluded CASP10, BARD1, XRCC5, and
PPP1R7 as targets of mutational inactivation of
these deletions in CC. Further, we have identified an
indirect epigenetic effect on a number of genes linked
to methylation or deacetylation mechanisms, or both.
These results should further aid in identifying the
TSGs at the 2q-deleted region in cervical carcino-
genesis. In the present study, we also have detected
LOH at 2q35–q37 regions in 85% of precancerous
lesions, both high grade and low grade. Our data,
therefore, support the hypothesis that 2q deletions
occur very early in cervical carcinogenesis and that
the TSG affected by these deletions may play a role in
the progression of precancerous lesions to invasive
cancer. Thus, the 2q genetic deletions identified in
invasive CC and in precursor lesions may have biologic
and clinical implications. Biologically, the identification
of target TSG at 2q deletions will provide a better
understanding of the genetic basis of cervical carcino-
genesis. Since only a fraction of precancerous lesions
have the potential to progress to invasive cancer (zur
Hausen and Rosl, 1994), the 2q-specific gene alterations
may facilitate the clinical identification of dysplasias at
high risk for progression. The chromosomal amplifica-
tions reported here have the potential to uncover
amplified genes. Molecular characterization of these
chromosomal changes utilizing the new genomic tech-
nologies should provide important advances in our
understanding of the genetic mechanisms of initiation
and progression. The identification of amplified genes
will provide new insights into the clinical behavior and
management of CC.
Materials and methods
Tumor-normal tissues and cell lines
We analysed 98 tumor biopsies consisting of 65 frozen tumors
from previously untreated primary invasive CCs with the
corresponding peripheral blood samples, and 33 formalin-
fixed, paraffin-embedded specimens from CINs. The tissues
were obtained from patients treated at the Instituto Nacional
de Cancerologia, Santa Fe de Bogota, Colombia and from the
Department of the Obstetrics and Gynecology of Friedrich
Schiller University, Jena, Germany after appropriate informed
consent and approval of the protocols by the institutional
review boards. The invasive tumors were clinically classified as
FIGO stage IB (eight tumors), IIB (16 tumors), IIIB (37
tumors), and IV (four tumors). Histologically, 60 tumors were
classified as squamous cell carcinomas and five as adenocarci-
nomas. A total of 28 CIN specimens were classified as high-
grade and five as low-grade lesions. Eight CC cell lines SiHa,
SW756, C-4I, Ca Ski, C-33A, HT-3, MS751, and ME-180 were
obtained from the American Type Culture Collection (ATCC,
Manassas, VA, USA), and were grown in tissue culture
according to the supplier’s recommendations.
Microdissection, DNA and RNA isolation, and LOH analysis
High-molecular weight DNA from frozen tumor and periph-
eral blood specimens, and frozen cell pellets from cell lines
was isolated as previously described (Pulido et al., 2000).
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Tumor cells from paraffin-embedded CIN tissue specimens
were isolated by laser capture microdissection (Arcturus,
Mountain View, CA, USA) after methyl green staining and
the extraction of DNA as described earlier (Chatterjee et al.,
2001). Total RNA was isolated from semiconfluent cell
cultures using TRIzol reagent (Life Technologies, Gaithers-
burg, MD, USA) according to the manufacturer’s protocol. A
panel of 31 sequence-tagged repeat polymorphic (STRP) (27
di- and four tetra-nucleotide) markers was chosen on the basis
of their map position and heterozygosity (Figure 2) (Gene
Map 99-http://www.ncbi.nlm.nih.gov/genemap). A standard
polymerase chain reaction (PCR) containing gamma [32P]ATP
end-labeled forward primer, analysis of PCR products on
denaturing polyacrylamide sequencing gels, and scoring of
LOH on autoradiograms were performed as previously
described (Mitra et al., 1995; Pulido et al., 2000). All
autoradiograms were visually analysed. The definition of
minimal region of deletion was defined earlier (Chatterjee
et al., 2001). The LOH analysis was performed at least twice on
all tumors with the corresponding markers that define the
minimal deletion.
Comparative genomic hybridization
CGH analysis was performed as previously described (Rao
et al., 1998). Briefly, labeled tumor (fluorescein-12-dUTP;
NEN-DuPont, Boston, MA, USA) and normal (Texas Red-5-
dUTP; NEN-DuPont, Boston, MA, USA) DNAs were mixed
in equal amounts in the presence of human Cot-1 DNA
(GIBCO/BRL, Gaithersburg, MD, USA), and were hybri-
dized to normal human metaphase chromosomes. Seven to 10
metaphases from DAPI counter-stained slides were captured
for each tumor using a cooled charge-coupled device camera
attached to a Nikon Eclipse 800 microscope and processed
using the Quantitative Image Processing System (Applied
Imaging, Santa Clara, CA, USA). Red, green, and blue
fluorescence intensities were analysed for all metaphases,
normalized to a standard length, and statistically combined
to show the red : green signal ratio and 95% confidence
intervals for the entire chromosome. Copy-number changes
were detected based on the variance of the red : green ratio
profile from the standard of 1.0. Ratio values of 1.20 and 0.80
were used as upper and lower thresholds to define gains and
losses, respectively. High-level amplification was defined as the
occurrence of fluorescein intensity values in excess of 2.0 along
with a strong localized fluorescein isothiocynate (FITC) signal
at the chromosomal site.
Analysis of mutations and gene expression
Single-strand conformational polymorphism (SSCP) analysis
was performed on all coding exons using primers flanking
intronic sequences of four candidate genes. These were protein
phosphatase 1, regulatory subunit 7 (PPP1R7) (Renouf et al.,
1995), caspase 10, apoptosis-related cysteine protease
(CASP10) (Vincenz and Dixit, 1997), BRCA1-associated
RING domain 1 (BARD1) (Wu et al., 1996), and X-ray repair
complementing defective repair in Chinese hamster cells 5
(double-strand break rejoining; Ku autoantigen) XRCC5
(Taccioli et al., 1994). Standard PCR was performed using
25 ng of DNA in the presence of 0.5 mCi of alpha [32P]dCTP.
The diluted PCR products were denatured in sequencing stop
buffer and was run overnight at room temperature in 6%
nondenaturing polyacrylamide gels containing 10% glycerol.
Dried gels were autoradiographed and examined for con-
formational changes. Purified PCR products were sequenced
for all exons that showed conformational variations. Primer
sequence information and the PCR conditions of these genes
are available from authors on request.
To assess gene expression, total RNA isolated from the cell
lines was reverse transcribed using random primers and the
Pro-STAR first strand RT–PCR kit (Stratagene, La Jolla, CA,
USA). Semiquantitative analysis of gene expression was
performed in replicate experiments by 26–28 cycles of multi-
plex RT–PCR with b-actin as control and gene-specific primers
spanning at least two exons. The gene primers used and their
positions in cDNA were:
The PCR products were run on 1.5% agarose gels,
visualized by ethidium bromide staining and quantified using
the Kodak Digital Image Analysis System (Kodak, New
Haven, CT, USA). The effect of methylation on gene
expression was similarly assessed on total RNA isolated from
the cell lines treated with the demethylating agent 5-Aza-20
deoxycytidine (Sigma) for 5 days at a concentration of 5mm,
the deacetylase inhibiting agent n-butyric acid (Sigma) for 24 h
at a concentration of 5 mm or with both of these agents.
Analysis of promoter hypermethylation
Methylation-specific PCR (MSP) was performed with primers
designed specific for methylated and unmethylated DNA as
previously described (Herman et al., 1996). These primers
were:
CFLAR-F 50-CTTGGCCAATTTGCCTGTAT (535–554 bp)
CRLAR-R 50-CTCGCTTCTGAGCCTTGAAT (810–829 bp)
(product size-295 bp)
CASP10-F 50-ACCCGACAAAGGGTTTCTCT (516–535 bp)
CASP10-R 50-GATACGACTCGGCTTCCTTG (800–819 bp)
(product size-304 bp)
CASP10-F2 50-AAGAGGAAGTGGAGCGACTG (490–509 bp)
CASP10-R2 50-GTCCTCCAGGCATGTCAGAT (691–710 bp)
(product size-221 bp)
CASP8-F 50-GTCTGTACCTTTCTGGCGGA (616–635 bp)
CASP8-R 50-ACTCCTCCCCTTTGCTGAAT (892–911 bp)
(product size-296 bp)
BARD1-F 50-CATGGGCACCTGAAGGTAGT (1484–1503 bp)
BARD1-R 50-AAGAGGTCCATCCCTACGCT (1764–1783 bp)
(product size-300 bp)
XRCC5-F 50-ATCCCCATTTGAACAAGCAA (117–136 bp)
XRCC5-R 50-AATCACATCCATGCTCACGA (368–387 bp)
(product size-271 bp)
PPP1R7-F 50-AGAATCTGGAGGCGCTAACA (422–441 bp)
PPP1R7-R 50-CCCCAAAAACAAACTCTCCA (644–663 bp)
(product size-242 bp)
NCL-F 50-CAGCCAAAGCAGTTACCACA (410–429 bp)
NCL-R 50-GGTGCTTCTTTGACAGGCTC (922–949 bp)
(product size-532 bp)
NEDD5-F 50-CCTGGCTATGGTGACGCTAT (565–584 bp)
NEDD5-R 50-TCTGGGTTCTCCACTTCCAC (1045–1064 bp)
(product size-500 bp).
BARD1 U-F 50-TATTAATGTGAGTAGTGTAGTA; U-R 50-CACCATCCCAAACACAAAAAA
BARD1 M-F 50-TATTAACGCGAGTAGCGTAG; M-R 50-CGCCGTCCCAAACGCGAA
PPP1R7 U-F 50-GTGTGGTTTTATGATGGAATTA; U-R 50-ACAACTATTACTACCCCACAC
PPP1R7 M-F 50-GCGCGGTTTTATGACGGAAT; M-R 50-ACGACTATTACTACCCCGCG
CFLAR U-F1 50-TTGGTTTATTTATGTTTGGGTAG; U-R1 50-CAATAAATAACAAAAATTAAACATAA
CFLAR M-F1 50-TCGGTTTATTTACGTTCGGGTA; M-R1 50-CGATAAATAACGAAAATTAAACGTA
CFLAR U-F2 50-TTGTAAAGTTTGTGGTAAATAATTG; U-R2 50- CACACTAACAACACCAAAACTAT
CFLAR M-F2 50-TCGTAAAGTTCGCGGTAAATAATC; M-R2 50- GCGCTAACGACGCCGAAACTA
(underlined letters indicate converted nucleotides).
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Briefly, tumor DNA was modified by sodium bisulphite
treatment. We used placental DNA treated in vitro with SssI
methyltransferase (New England Biolabs, Beverly, MA, USA)
and normal lymphocyte DNA treated similarly to tumor
DNAs as positive controls for methylated and unmethylated
templates, respectively. PCR products were run on 2% agarose
gels and viewed after ethidium bromide staining. PCR
products generated from bisulfite-converted tumor DNA were
sequenced to identify partially methylated residues.
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